Source: Eur Respir Monogr 2015; 68: 234-246
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Nevin Murray, Krista L. Noonan. Can we expect progress from targeted therapy of SCLC?. Eur Respir Monogr 2015; 68: 234-246

Member's Comments

No comment yet.

Related content which might interest you: Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Why can initial treatment of localised lung cancer fail? Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007 Successful targeted therapy of advanced lung cancer Source: Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session Year: 2013 A preliminary study on targeted therapies in advanced lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 How novel targeted therapies have changed patient outcomes in ALK+ NSCLC Source: International Congress 2015 – Multidisciplinary approaches in the personalized care of the ALK + NSCLC patient Year: 2015 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 What specific issues arise in the management of elderly patients with advanced NSCLC? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 Pushing the limits, real benefit for the patient ? – a curative treatment approach in an unfit lung cancer patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017